- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04151758
Effect of Docosahexaenoic Acid Supplementation on Microbiome in Obese ChiLdrEn. (DAMOCLE)
Effect of Docosahexaenoic Acid Supplementation on Microbiome in Obese ChiLdrEn. The DAMOCLE Study
Study Overview
Status
Conditions
Detailed Description
Differences in gut microbiota composition and function will be evaluated in obese children before starting the DHA supplementation and dietary-lifestyle intervention, at the end of DHA supplementation (4 months) e after 4 months of dietary dietary-lifestyle intervention without DHA supplementation. The investigators will identify the role of DHA on the intestinal microbiota and indicative species related to insulin resistance (IR). The investigators will determine whether DHA supplementation, combined with interventions to improve diet and lifestyle, reduces adverse metabolic consequences together with their co-morbidities.
The following tasks will be also performed at t0, t1 and t2:
Clinical examination including: physical examination, Tanner score evaluation; Bristol Stool Chart Blood pressure will be checked in all children by using oscillometric devices validated in the pediatric age group.
Anthropometry including body circumferences and skinfolds, calculation of BMI z scores and body composition. Body composition will be assessed using an air displacement plethysmography system (BOD POD COSMED-USA).
Dietary assessment:
- Food intakes will be recorded by prospective 3-d weighed food records obtained with food scales. Parents will be advised on how to record all food and beverages consumed during 2 weekdays and 1 weekend day. Quantification and analysis of the energy intake and nutrient composition will be performed with an ad hoc PC software (MètaDieta®, Me.Te.Da S.r.l., San Benedetto del Tronto, Italy).
Mediterranean Diet Quality Index (KIDMED) questionnaire for Mediterranean Diet assessment. The KIDMED index ranges from 0 to 12, and is based on a 16-question test that can be self-administered. The sums of the values from the administered test will be classified into three levels:
8 or more: optimal Mediterranean diet; 4-7: improvement needed to adjust intake to Mediterranean patterns. 3 or less: very low diet quality.
Hematological and biochemical status including:
Complete cell blood count;
Metabolic and nutritional parameters according to local routines for childhood obesity (fasting glucose, fasting insulin, LDL, HDL, total cholesterol, triglycerides, Apolipoprotein A and Apolipoprotein B levels, transaminases and amma-glutamyl transferase). Oral Glucose Tolerance Test (OGTT) will be performed. The insulin sensitivity and insulin resistance was assessed by calculating HOMA index (Homeostasis Model Assessment) and QUICKI (Quantitative Insulin-Sensitivity Check Index), using the following formulas:
HOMA: fasting plasma insulin in mU/l x FPG in mmol/l/22.5 QUICKI: 1/(log10 fasting plasma insulin in mU/l + log10 glucose in mg/dl)
Inflammatory index (VES, high-sensitive CRP, including fecal calprotectin)
Liver ultrasonography for detection of fatty liver disease
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Elvira Verduci, PhD
- Phone Number: +39 3934771218
- Email: elvira.verduci@unimi.it
Study Locations
-
-
-
Milan, Italy, 20142
- Recruiting
- Ospedale San Paolo
-
Contact:
- Elvira Verduci, MD PhD Assistant Professor
- Phone Number: +39 0281844508
- Email: elvira.verduci@unimi.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 6 <Age <14 years
- Severe obesity (>3 DS) according to WHO classification.
- Gestational age: 37-42 weeks.
- Birth-weight: > 2500 g e < 4000 g
- Caucasian
Exclusion Criteria:
- secondary obesity
- supplementation with pre/probiotics (in the previous 3 months);
- antibiotic treatment (in the previous 3 months);
- chronic or acute intestinal diseases (in the previous 3 months).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Docosahexaenoic Acid Supplementation, lifestyle intervention
Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day.
Physical activity and healthy eating habits will be encouraged.
|
Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day (2 ml per day DHA RICH OIL 25% aroma mandorla FoodAR Limbiate, Italy;50% DHA oil obtained from Schyzochitrium sp ; Martek Biosciences Corporation, Columbia, Maryland, USA) to all participants of the study.
DHA 2 ml will provide about 16 kcal of energy.
Other Names:
All participants will underwent a visit at t0, t1 and t2 in which physical activity will be promoted according to Italian dietary guidelines for childhood obesity.
All participants will underwent a visit at t0, t1 and t2 in which healthy food habits will be promoted according to Italian dietary guidelines for childhood obesity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in gut microbiota composition.
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on gut microbiota composition and metabolite production.
Differences in gut microbiota composition and function will be evaluated in obese children's stools before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
Study of the microbiota biodiversity will be performed by high-throughput sequencing techniques (16S rRNA gene sequencing) in order to establish whether postbiotics could modulate the microbial composition in obese children
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in short-chain fatty acid production by gut microbiota
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on gut microbiota composition and metabolite production.
Differences in gut microbiota composition and function will be evaluated in obese children's stools before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
Analysis of short chain fatty acids concentration by gas-chromatography (GC-FID) will be performed in order to monitor the effect of postbiotics intake modulating microbial metabolite production
|
t0: 0 t1: +4 months t2: +8 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in total cholesterol levels
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in LDL cholesterol levels
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in HDL cholesterol levels
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in triglycerides levels
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in fasting glucose levels
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in fasting insulin levels
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in HOMA index (Homeostasis Model Assessment)
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in QUICKI (Quantitative Insulin-Sensitivity Check Index)
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in alanine aminotransferase (ALT) levels
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in aspartate aminotransferase (ALT) levels
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in gamma glutamyl transferase (GGT) levels
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in body mass index
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in waist circumference
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in triceps skinfold
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in systemic arterial blood pressure
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Complete cell blood count
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in C-reactive protein (CRP) levels
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in erythrocyte sedimentation rate (ESR)
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in fecal calprotectin levels
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
|
t0: 0 t1: +4 months t2: +8 months
|
Changes in body mass composition
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
body mass composition will be assessed using an air displacement plethysmography system (BOD POD COSMED-USA)
|
t0: 0 t1: +4 months t2: +8 months
|
Oral glucose tolerance test (OGTT) result
Time Frame: t0
|
Fasting glucose and glucose levels after 2 hours from ingestion of a glucose-containing solution.
|
t0
|
Degree of fatty liver disease evaluated by echosonography of the liver
Time Frame: t0: 0 t1: +4 months t2: +8 months
|
Interventions aimed at improving diet and lifestyle, on anthropometrics data and glucose and lipid profile before starting the DHA supplementation (t0) and dietary-lifestyle intervention, at the end of DHA supplementation (t1: +4 months) and after 4 months of dietary dietary-lifestyle intervention without DHA supplementation (t2: +8 months).
body mass composition will be assessed using an air displacement plethysmography system (BOD POD COSMED-USA)
|
t0: 0 t1: +4 months t2: +8 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Elvira Verduci, Hospital San Paolo
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015/ST/135-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Childhood Obesity
-
Universiteit LeidenWageningen University; Nutricia, Inc.; Danone ResearchCompletedChildhood Obesity | Childhood Overweight | Vegetable Acceptance in Early ChildhoodNetherlands
-
Vanderbilt University Medical CenterActive, not recruitingPediatric Obesity | Childhood Obesity | Childhood Onset ObesityUnited States
-
Tehran University of Medical SciencesUnknownChildhood Obesity PreventionIran, Islamic Republic of
-
Oregon State UniversityCompletedChildhood Obesity Prevention
-
The Miriam HospitalHassenfeld Child Health Innovation InstituteCompletedChildhood Obesity PreventionUnited States
-
Fundacion para la Formacion e Investigacion Sanitarias...UnknownChildhood Obesity PreventionSpain
-
Tampere UniversitySeinajoki Central Hospital; Tampere University Hospital; Foundation for Paediatric... and other collaboratorsCompleted
-
Cornell UniversityCompletedChildhood Obesity Prevention
-
Harokopio UniversityCompletedPrevention of Childhood ObesityGreece
-
University of Alabama at BirminghamCompletedObesity, Childhood | Overweight, ChildhoodUnited States
Clinical Trials on Docosahexaenoic Acid Supplementation
-
University of the Balearic IslandsInstituto de Salud Carlos IIICompletedExercise | Oxidative Stress | Athletic Performance | Training Season | Antioxidant CapabilitiesSpain
-
William CoryellTerminatedMajor Depressive Disorder in Pregnancy
-
William CoryellTerminatedMajor Depressive Disorder in Pregnancy
-
Universidad de GranadaPuleva BiotechCompletedInflammation | Oxidative Stress | Infant DevelopmentSpain
-
Ludwig-Maximilians - University of MunichGerman Research Foundation; German Federal Ministry of Education and Research; Société des Produits Nestlé (SPN)CompletedPrematurity of FetusGermany
-
Pontificia Universidad Catolica de ChileUniversity of Chile; Laboratorio Gynopharm - CFRUnknownPremature Birth | Fetal Growth Retardation | Preeclampsia | StillbirthChile
-
University of TorontoIovate Health Sciences International IncCompletedExercise | Metabolism | Amino Acids, EssentialCanada
-
Instituto Mexicano del Seguro SocialHospital Civil de GuadalajaraCompletedHuman Immunodeficiency Virus
-
Indiana UniversityCompleted
-
University of Kansas Medical CenterOhio State University; Nationwide Children's Hospital; University of CincinnatiCompleted